Revolutionizing Nuclear Medicine
ARTMS is a global leader in solid target technology and our products enable our partners to produce several high value diagnostic isotopes including:
We deliver state-of-the-art technology to fully enable your medical isotope production.
Our team ensures your staff is expertly trained and supported ensuring the most reliable radiopharmaceutical production
The Quantm Irradiation System (QIS® ) enables turnkey production of purified radiometals. Consisting of an automatic 2-way pneumatic transfer, compact solid target station and complete solid target processing solutions the QIS® expands your research, production, and distribution capabilities.
Precision medicine is the future. We support clinical researchers, biotech and pharmaceutical drug innovators, and pharmaceutical distributors in the development and commercialization of high volumes of unique isotopes such as Gallium-68 and Zirconium-89.
Solving Isotope Shortage and the Growing Demand for Theragnostics
patients last year did not receive scheduled nuclear medicine procedure due to supply chain issues
of the current nuclear medicine reactor supplier base will go offline over the next decade
Can the global demand for isotopes could be met without relying on a single-point-of-failure supply chain or low capacity generators?
ARTMS Supply Model
QISTM System provides for cost-effective, decentralized, and local production of important medical isotopes, such as Gallium-68 (68Ga), Technetium-99m (99mTc), Zirconium-89 (89Zr) and Copper-64 (64Cu) using existing hospital or commercially based medical cyclotrons.
Mr. Conroy is the Chief Executive Officer (CEO) of ARTMS. Mr. Conroy brings to ARTMS more than 25 years of experience in the life sciences industry, including several significant senior positions within the radiopharmaceutical industry. Most recently Mr. Conroy was the General Manager of Jubilant Pharma where he was responsible for North American sales and operations.
Dr. Michael Cross PhD, MBA, is the Chief Operating Officer of ARTMS and has responsibilities that include business and corporate development, strategy and operations. Dr. Cross has over 20 years of industry experience with a successful background in venture capital financing, operations and business development transactions.
Dr. Paul Schaffer is CTO of ARTMS and Head of TRIUMF’s Life Sciences division. Paul came to TRIUMF in 2009 from the private sector where he worked at General Electric in upstate New York. He earned his Ph.D. in chemistry from McMaster University in 2003 and earned his B.Sc. with honours in chemistry and biochemistry from the University of British Columbia (UBC) in 1998